Shares in gene therapy developer uniQure have risen more than 75% after the company reported that Huntington’s disease candidate AMT-130 slowed down the progression of the disorder over two
Novartis has doubled down on its gene therapy collaboration with Voyager Therapeutics, stumping up another $1.2 billion-plus in potential milestone payments and directing
Tucked away inside Novartis' fourth-quarter results update this morning is the news that the company has pulled the plug on a drug candidate for Huntington's disease after
A prominent genetics professor at Stanford University in the US has paid $29 million to investors in Nuredis – a biotech that has now been wound up – after a California court found he misre
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh